Evidence map›Paper›PMID 29709783›Full record

ArticleJournal of pharmaceutical and biomedical analysis2018

Development and validation of an LC-MS/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid.

Andrew J Ocque, Colleen E Hagler, Gene D Morse, Scott L Letendre, Qing Ma

Abstract readValidation Study
In one paragraph

Article in Journal of pharmaceutical and biomedical analysis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Switching to Tenofovir Alafenamide in Elvitegravir-Based Regimens: Pharmacokinetics and Antiviral Activity in Cerebrospinal Fluid.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Andrew J OcqueTranslational Pharmacology Research Core, Center for Integrated Global Biomedical Sciences, New York State Center of Excellence in Bioinformatics and Life Sciences, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA. Electronic address: ocque@buffalo.edu.
Colleen E HaglerTranslational Pharmacology Research Core, Center for Integrated Global Biomedical Sciences, New York State Center of Excellence in Bioinformatics and Life Sciences, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA.
Gene D MorseTranslational Pharmacology Research Core, Center for Integrated Global Biomedical Sciences, New York State Center of Excellence in Bioinformatics and Life Sciences, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA.
Scott L LetendreDepartment of Medicine, University of California, San Diego, CA, USA.
Qing MaTranslational Pharmacology Research Core, Center for Integrated Global Biomedical Sciences, New York State Center of Excellence in Bioinformatics and Life Sciences, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA.
University at Buffalo, State University of New York · USUniversity of California San Diego · US

Funding

Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
STRUCTURAL NEUROIMAGING COREP30MH062512 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jennifer E Iudicello · 2001 to 2026
$50.4M
University of Rochester HIV/AIDS Clinical Trials Unit Administrative SupplementUM1AI069511 · NIAID · UNIVERSITY OF ROCHESTER · PI Paul R Bohjanen, MICHAEL C KEEFER · 2012 to 2026
$25.7M
Virology/Immunology CoreP30AI078498 · NIAID · UNIVERSITY OF ROCHESTER · PI DEWHURST, STEPHEN · 2008 to 2018
$14.6M
Antiretroviral pharmacogenomics, pharmacokinetics and toxicity in neuroAIDSK08MH098794 · NIMH · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MA, QING · 2012 to 2016
$599k
NIAID NIH HHS P30 AI078498NIAID NIH HHS UM1 AI069511NIAID NIH HHS UM1 AI106701NIMH NIH HHS K08 MH098794NIMH NIH HHS P30 MH062512
6 · The paper itself

Abstract

A liquid chromatography with triple quadrupole mass spectrometry method was developed and validated for the determination of tenofovir and tenofovir alafenamide concentrations in human plasma and cerebrospinal fluid. Tenofovir and tenofovir alafenamide were extracted from matrix by solid phase extraction. The dried extraction eluents were dissolved in water for LC-MS/MS analysis. Separation was achieved with a Phenomenex Synergi 4 μm Polar-RP 80A column (50 × 2 mm) with a gradient elution of 0.1% formic acid in water and acetonitrile. The total run time was 5 min. Detection of analytes was achieved using electrospray ionization (positive mode) and triple quadrupole selected reaction monitoring. Standard curve concentrations ranged from 0.5 to 500 ng/mL for the plasma assay and 0.1-50 ng/mL for the cerebrospinal fluid assay. The intra- and inter-day accuracy and precision were less than 12% in low, medium, and high quality control samples for both matrices. The validated methods were applied to the analysis of plasma and cerebrospinal fluid samples of a patient undergoing tenofovir therapy which involved the switch from Stribild

Indexed as

AdenineAlanineAnti-HIV AgentsChromatography, High Pressure LiquidCobicistatDrug CombinationsElvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationEmtricitabineHIV InfectionsHumansQuinolonesReproducibility of ResultsSolid Phase ExtractionTandem Mass SpectrometryTenofovirAdenineAlanineAnti-HIV AgentsCobicistatDrug CombinationsElvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationEmtricitabineQuinolonesTenofovirtenofovir alafenamideCerebrospinal fluidMass spectrometryPlasmaTenofovirTenofovir alafenamide

Identifiers

PMID29709783
PMCPMC5984727
OpenAlexW2800353572

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.